Gerilimzumab

Drug Profile

Gerilimzumab

Alternative Names: ARGX 109; GB 224; RYI 008

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator arGEN-X
  • Developer argenx; Bird Rock Bio
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Interleukin-6 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis
  • Preclinical Autoimmune disorders
  • No development reported Cancer; Ovarian cancer; Renal cell carcinoma

Most Recent Events

  • 03 Jan 2017 ANVISA and CONEP grant approval for conducting a phase II trial for Rheumatoid arthritis in Brazil
  • 24 Dec 2016 Genor Biopharma received a clinical trial approval from China Food and Drug Administration for gerilimzumab
  • 11 Nov 2016 Adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in healthy volunteers presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top